Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study
Hongjie Cai,Song Chen,Zhiqiang Wu,Fan Wang,Shuangyan Tang,Ludan Chen,Wenbo Guo
DOI: https://doi.org/10.2147/jhc.s439001
2024-02-27
Journal of Hepatocellular Carcinoma
Abstract:Hongjie Cai, 1 Song Chen, 2 Zhiqiang Wu, 1 Fan Wang, 1 Shuangyan Tang, 1 Ludan Chen, 1 Wenbo Guo 1 1 Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510062, People's Republic of China; 2 Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center and Sun Yat-Sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China Correspondence: Wenbo Guo, Email Purpose: Local in combination with systemic therapy might be an option for patients with advanced unresectable hepatocellular carcinoma (uHCC). This study examined the clinical benefits and adverse events (AEs) of first-line transarterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC) combined with atezolizumab (Atezo) and bevacizumab (Bev) in patients with uHCC of a diameter larger than 8 cm. Patients and methods: This retrospective study included patients with uHCC of a diameter larger than 8 cm who were treated with first-line Atezo-Bev and TAE+HAIC at the First Affiliated Hospital of Sun Yat-Sen University between September 30, 2019, and September 30, 2022. Progression-free survival (PFS), overall survival (OS), tumor response according to mRECIST, and AEs were analyzed. Multivariable Cox analyses were performed to examine the factors associated with PFS. Results: Thirty patients were included. The objective response rate (ORR) was 74.4% (95% confidence interval [CI], 59.3%-89.5%), and the disease control rate (DCR) was 93.3% (95% CI, 85.4%-98.6%). The median follow-up was 11.4 (inter-quartile range [IQR], 5.5– 17.9) months. The median PFS was 6.8 (95% CI, 2.6– 11.1) months. The 3-, 6-, 9-, and 12-month survival rates were 86.2%, 82.5%, 68.6%, and 60%, respectively. The median OS was not estimated. Extrahepatic metastasis was independently associated with PFS (hazard ratio [HR]=3.468, 95% CI, 1.001– 12.023). The most common AEs were fever (46.7%). Grade 4 AEs occurred one time as hematemesis but no 5 AEs were observed. Conclusion: Atezo-Bev combined with TAE and HAIC might benefit patients with uHCC of a diameter larger than 8 cm, with manageable AEs. Keywords: immune checkpoint inhibitors, tyrosine kine inhibitors, local therapy, systemic therapy, large unresectable hepatocellular carcinoma Hepatocellular carcinoma (HCC) is a highly lethal invasive carcinoma arising in the liver, 1 with an estimated 905,677 new cases and 830,180 deaths in 2020. 2 China has a high prevalence of hepatitis B and C and a consequent high incidence of hepatitis-related HCC. 3 Unfortunately, only 30–40% of the patients are amenable to surgery. 4 Trials showed that transarterial embolization (TAE) and transarterial chemoembolization (TACE) could achieve benefits in selected patients with unresectable HCC (uHCC). 5–7 The Chinese guidelines recommend TACE for China liver cancer staging (CNLC) grade IIb, IIIa, and part of IIIb and hepatic arterial infusion chemotherapy (HAIC) for uHCC. 8 TAE and TACE can reduce tumor burden effectively and rapidly by causing an ischemic injury, leading to tumor regression in up to 50% of the patients. 9–12 In recent years, HAIC with FOLFOX alone or in combination with tyrosine kine inhibitors (TKIs) has improved survival in patients with advanced HCC in China, 13–15 especially in patients with portal vein tumor thrombosis (PVTT) 13,16–18 and patients with large uHCC. 19 According to the Barcelona Clinic liver cancer (BCLC) stage, atezolizumab (Atezo) plus bevacizumab (Bev) is the preferred first-line treatment of HCC patients with BCLC stage C. 20–22 The IMbrave150 trial established the position of Atezo-Bev as the first-line treatment for advanced HCC. 20 However, the patients with large uHCC were underrepresented in the IMbrave150 trial, and Atezo-Bev appeared to have limited efficacy in these patients, with a median overall survival (OS) of 7.6 months. 20,21 In patients with high-risk uHCC, such as those with larger than 8 cm in diameter, 22 the effect of first-line systemic therapy alone is limited. In order to improve survival in patients with advanced uHCC, a combination of locoregional and systemic therapies is recommended. 23,24 HAIC can be combined with lenvatinib and immune checkpoint inhibitors (ICIs). 25–27 Although triple therapy had a high objective response rate (ORR), 40.5% of the patients still did not respond. 28 According to the LAUNCH trial, TACE in combination with lenva -Abstract Truncated-
oncology